0000000000275349

AUTHOR

Gioacchino Di Paola

showing 10 related works from this author

Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by (18)FDG-PET/CT

2017

Abstract Objectives The objective of this study was to investigate fludeoxyglucose F 18 positron emission tomography/computed tomography ( 18 FDG-PET/CT) parameters as predictive of response after stereotactic ablative radiotherapy (SABR) for lung oligometastases. Methods The inclusion criteria of the current retrospective study were as follows: (1) lung oligometastases treated by SABR, (2) presence of 18 FDG-PET/CT before and after SABR for at least two subsequent evaluations, (3) Karnofsky performance status higher than 80, and (4) life expectancy longer than 6 months. All patients were treated with a biologically equivalent dose of at least 100 Gy with an alpha/beta ratio of 10. The foll…

MaleFludeoxyglucose F-18Lung Neoplasmsmedicine.medical_treatment18FDG-PET/CT; Lung malignancies; Predictive factors; SABR; Adenocarcinoma; Aged; Aged 80 and over; Carcinoma Non-Small-Cell Lung; Carcinoma Squamous Cell; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence Local; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tumor Burden; Radiosurgery; Oncology; Pulmonary and Respiratory MedicineSABR volatility model030218 nuclear medicine & medical imaging0302 clinical medicinePositron Emission Tomography Computed TomographyAblative case80 and overMedicineNon-Small-Cell LungSABRmedicine.diagnostic_test(18)FDG-PET/CTMiddle AgedPrognosisTumor Burdenmedicine.anatomical_structureLocalOncologyPositron emission tomography030220 oncology & carcinogenesisLymphatic MetastasisFemaleRadiologyPredictive factorsPulmonary and Respiratory Medicinemedicine.medical_specialtyLung malignanciesStandardized uptake value18FDG-PET/CTAdenocarcinomaRadiosurgery03 medical and health sciencesFluorodeoxyglucose F18HumansAgedNeoplasm StagingRetrospective StudiesLungbusiness.industryCarcinomaRetrospective cohort studyRadiation therapyNeoplasm RecurrenceSquamous CellRadiopharmaceuticalsbusinessNuclear medicineFollow-Up Studies(18)FDG-PET/CT; Lung malignancies; Predictive factors; SABR
researchProduct

Stereotactic body radiation therapy for liver oligometastases: predictive factors of local response by 18F-FDG-PET/CT

2018

Objective:To investigate metabolic parameters as predictive of local response after stereotactic body radiation therapy (SBRT) for liver-oligometastases.Methods:Inclusion criteria of the present re...

medicine.medical_specialtyStereotactic body radiation therapybusiness.industryLiver NeoplasmsHumans; Liver Neoplasms; Retrospective Studies; Treatment Outcome; Fluorodeoxyglucose F18; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Radiosurgery; Radiology Nuclear Medicine and ImagingGeneral MedicineRadiosurgery030218 nuclear medicine & medical imaging03 medical and health sciencesTreatment Outcome0302 clinical medicineFluorodeoxyglucose F18Positron Emission Tomography Computed TomographyNuclear Medicine and Imaging030220 oncology & carcinogenesisHumansMedicineRadiology Nuclear Medicine and imagingFdg pet ctRadiologyRadiopharmaceuticalsRadiologybusinessRetrospective StudiesThe British Journal of Radiology
researchProduct

Weekly Cisplatin and Volumetric-Modulated Arc Therapy With Simultaneous Integrated Boost for Radical Treatment of Advanced Cervical Cancer in Elderly…

2016

Background: To evaluate the feasibility and clinical preliminary results of weekly cisplatin and volumetric-modulated arc therapy to the pelvis with simultaneous integrated boost to macroscopic disease in a cohort of elderly patients. Materials and Methods: Inclusion criteria of this prospective study were age ≥70 years, Karnofsky performance status 70 to 100, locally advanced histologically proven squamous cervical carcinoma, and patients unable to undergo brachytherapy. Radiation doses prescribed were 66 Gy to the macroscopic disease and 54 Gy to the pelvic nodes in 30 fractions. Weekly cisplatin dose was 40 mg/mq. Results: A total of 30 patients were recruited. Median follow-up was 32 mo…

Simultaneous integrated boostMalemedicine.medical_specialtyCancer ResearchBrachytherapyUterine Cervical NeoplasmsVMATelderly patients030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineWeekly cisplatinmedicineArc therapyHumansAgedCervical cancerRadical treatmentAged 80 and overbusiness.industryRadiotherapy DosageArticlesmedicine.diseaseVolumetric modulated arc therapyCombined Modality TherapySurgeryOncology030220 oncology & carcinogenesisCarcinoma Squamous CellVMAT; advanced cervical cancer; elderly patients; gynecological malignanciesFemaleadvanced cervical cancer; elderly patients; gynecological malignancies; VMAT; Oncology; Cancer ResearchRadiologyDose Fractionation RadiationLymph NodesRadiotherapy Intensity-ModulatedCisplatinbusinessgynecological malignanciesadvanced cervical cancer
researchProduct

Predictors of mucositis in oropharyngeal and oral cavity cancer in patients treated with volumetric modulated radiation treatment: A dose-volume anal…

2015

Background The purpose of this study was to assess predictors of mucositis in oropharyngeal and oral cavity cancer after definitive or adjuvant volumetric modulated arc radiotherapy (VMAT) +/− chemotherapy. Methods Fifty patients were evaluated. Statistical analysis was performed for the following parameters as potential predictors of mucositis ≥ G2: total oral mucosa and oral mucosa minus target high-low radiation dose regions (planning target volumes [PTVs]), mean dose (Dmean), maximum dose (Dmax), chemotherapy, weight loss, and dysphagia. Results Mucositis ≥ G2 was found to be statistically related to chemotherapy, weight loss, dysphagia ≥ G2, total oral mucosa Dmean ≥50 Gy and Dmax ≥65 …

Chemotherapymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentCancerOral cavitymedicine.diseaseDysphagia030218 nuclear medicine & medical imagingSurgeryRadiation therapy03 medical and health sciences0302 clinical medicinemedicine.anatomical_structureOtorhinolaryngologyWeight loss030220 oncology & carcinogenesisMucositisMedicinemedicine.symptomOral mucosabusinessNuclear medicineHead & Neck
researchProduct

Moderate hypofractionated helical tomotherapy for localized prostate cancer: preliminary report of an observational prospective study.

2019

Objective: To report preliminary findings of a phase II study exploring the clinical outcomes of moderate hypofractionated radiotherapy performed with helical tomotherapy (HT) using computed tomography–magnetic resonance imaging–based planning for localized prostate cancer. Methods: The phase II prospective study received ethics approval from our institutional ethics committee. A dose of 60 Gy/20 fractions for low–intermediate risk prostate cancer by means of HT was explored. Primary endpoints of the study were acute and late gastrointestinal (GI) and genitourinary (GU) toxicities. Secondary endpoints were quality of life and biochemical-free survival. Results: A total of 35 patients were i…

Hypofractionated RadiotherapyMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmenttomotherapyPhases of clinical researchTomotherapy030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancer0302 clinical medicinePreliminary reportProstatemedicineBiomarkers TumorHumansProspective StudiesNeoplasm MetastasisProspective cohort studyRadiometryProstate hypofractionation tomotherapyAgedNeoplasm StagingAged 80 and overhypofractionationbusiness.industryRadiotherapy Planning Computer-AssistedProstateProstatic NeoplasmsGeneral MedicineMiddle Agedmedicine.diseasehypofractionation; Prostate; tomotherapymedicine.anatomical_structureTreatment OutcomeOncology030220 oncology & carcinogenesisQuality of LifeObservational studyRadiation Dose HypofractionationRadiologyRadiotherapy Intensity-ModulatedbusinessFollow-Up StudiesTumori
researchProduct

Hippocampal dose during Linac-based stereotactic radiotherapy for brain metastases: An observational study

2017

Abstract Introduction Aim of the present study is to evaluate homolateral and contralateral hippocampus (H-H, C-H, respectively) dose during Fractionated Stereotactic Radiotherapy (FSRT) or Radiosurgery (SRS) for brain metastases (BM). Materials & methods Patients with BM   3 months, were considered for SRS/FSRT (total dose 15–30 Gy, 1–5 fractions). For each BM, a Flattening Filter Free (FFF) Volumetric Modulated Arc Therapy (VMAT) plan was generated with one or two arcs. Hippocampi were not considered during optimizations phase and were contoured and evaluated retrospectively in terms of dose: the Dmedian, Dmean, D0.1cc and the V1Gy, V2Gy, V5Gy and V10Gy were analyzed. Results From April 2…

AdultMalemedicine.medical_treatmentBiophysicsGeneral Physics and AstronomyStereotactic fractionatedHippocampal formationRadiation DosageRadiosurgeryHippocampusRadiosurgery030218 nuclear medicine & medical imagingStereotactic radiotherapyYoung AdultPhysics and Astronomy (all)03 medical and health sciences0302 clinical medicineNuclear Medicine and ImagingStereotactic radiotherapymedicineHumansRadiology Nuclear Medicine and imagingIn patientHippocampiAgedAged 80 and overRadiotherapyBrain Neoplasmsbusiness.industryRadiotherapy DosageBrain metastasesGeneral MedicineMiddle AgedBrain metastases; Hippocampi; Radiotherapy; Stereotactic fractionated; Stereotactic radiotherapy; Biophysics; Radiology Nuclear Medicine and Imaging; Physics and Astronomy (all)Volumetric modulated arc therapyRadiation therapy030220 oncology & carcinogenesisTotal doseFemaleDose reductionParticle AcceleratorsRadiologybusinessNuclear medicinePhysica Medica
researchProduct

Sequential boost in neoadjuvant irradiation for T3N0-1 rectal cancer: long-term results from a single-center experience.

2016

Purpose To evaluate the influence of radiation dose on tumor regression grade (TRG) and sphincter preservation rate in a series of cT3N0-1 rectal cancer patients treated with neoadjuvant chemoradiotherapy (CT-RT) with or without a sequential radiation boost. Materials and methods Between May 2002 and September 2013, 116 cases were eligible for retrospective evaluation. Radiotherapy was delivered for a total dose of 45 Gy (no boost arm) or 50.4 Gy (boost arm). TRG was evaluated with the Dworak scale. Results Median follow-up was 62 months (range, 12-138 months). The 5-year overall survival and local control rates were 72% and 93%, respectively. Fifty-five patients (47%) were treated with a s…

MaleCancer ResearchTime FactorsTumor downsizingColorectal cancermedicine.medical_treatmentAnal CanalKaplan-Meier EstimateSingle Center030218 nuclear medicine & medical imaging0302 clinical medicineAdjuvantNeoadjuvant therapyDigestive System Surgical ProceduresTumor Regression GradeIleostomyMedicine (all)Colorectal cancer; Radiation therapy; Tumor downsizing; Adenocarcinoma; Adult; Aged; Anal Canal; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Digestive System Surgical Procedures; Female; Fluorouracil; Follow-Up Studies; Gastrointestinal Tract; Humans; Ileostomy; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organ Sparing Treatments; Radiotherapy Dosage; Radiotherapy Adjuvant; Rectal Neoplasms; Retrospective Studies; Time Factors; Treatment Outcome; Urogenital System; Medicine (all); Oncology; Cancer ResearchRadiotherapy DosageGeneral MedicineChemoradiotherapyMiddle AgedNeoadjuvant TherapyRadiation therapyTreatment OutcomeOncology030220 oncology & carcinogenesisFemaleRadiologyFluorouracilmedicine.drugAdultmedicine.medical_specialtyUrogenital SystemAntineoplastic AgentsAdenocarcinomaCapecitabine03 medical and health sciencesmedicineHumansCapecitabineAgedNeoplasm StagingRetrospective StudiesRadiotherapybusiness.industryRectal Neoplasmsmedicine.diseaseColorectal cancerRadiation therapyGastrointestinal TractConcomitantRadiotherapy AdjuvantbusinessOrgan Sparing TreatmentsChemoradiotherapyFollow-Up StudiesTumori
researchProduct

Cone-beam computed tomography in lung stereotactic ablative radiation therapy: predictive parameters of early response

2016

To analyze lung lesion volume variations by contouring on cone-beam CT (CBCT) images to evaluate the early predictive parameters of stereotactic ablative radiation therapy (SABR) treatment response.The prescribed dose of SABR was varied according to the tumour site (central or peripheral) and maximum diameter of the lesions by using a strategy of risk-adapted dose prescription with a dose range between 48 and 70 Gy in 3-10 consecutive fractions. For the purpose of the analysis, the gross tumour volume (GTV) was recontoured for each patient at first and last CBCT using two lung levels/windows: (a) -600/1000 HU and (b) -1000/250 HU. Univariate analysis was performed to evaluate a correlation …

ContouringCone beam computed tomographyUnivariate analysismedicine.medical_specialtyLungFull Paperbusiness.industrymedicine.medical_treatmentGeneral MedicineSABR volatility modelEffective dose (radiation)030218 nuclear medicine & medical imagingRadiation therapy03 medical and health sciences0302 clinical medicinemedicine.anatomical_structureNuclear Medicine and Imaging030220 oncology & carcinogenesisAblative caseMedicineRadiology Nuclear Medicine and imagingRadiologyRadiologyNuclear medicinebusinessThe British Journal of Radiology
researchProduct

Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): A Mono-institutional Report on Fe…

2017

The aim of this study was to evaluate the acute toxicity profiles of a moderate hypofractionated regimen with volumetric modulated arc therapy (VMAT) in patients with prostate cancer (PC) who underwent radical prostatectomy.From December 2012 to February 2016, 125 patients, previously having undergone radical prostatectomy, received adjuvant (64 patients) or salvage (61 patients) radiotherapy (RT) inside an institutional protocol of moderate hypofractionation schedule using the VMAT technique (Varian RapidArc, Palo Alto, CA). Eligible patients were 85 years old, with an Eastern Cooperative Oncology Group performance status of 0 to 2, histologically proven adenocarcinoma of the prostate with…

MaleOncologymedicine.medical_specialtyUrologymedicine.medical_treatmentUrologyUrinary incontinenceDisease-Free Survival030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancersymbols.namesake0302 clinical medicineInternal medicinemedicineHumansAdjuvantFisher's exact testAgedNeoplasm StagingAged 80 and overProstatectomySalvage TherapyProstate cancerRadiotherapyAdjuvant; Hypofractionation; Prostate cancer; Radiotherapy; Salvage; Oncology; Urologybusiness.industryProstatectomyProstatic NeoplasmsCommon Terminology Criteria for Adverse EventsMiddle AgedProstate-Specific Antigenmedicine.diseaseAcute toxicityRadiation therapyRegimenTreatment OutcomeOncology030220 oncology & carcinogenesissymbolsHypofractionationSalvageRadiation Dose HypofractionationRadiotherapy AdjuvantRadiotherapy Intensity-Modulatedmedicine.symptombusinessRadiotherapy Image-GuidedClinical Genitourinary Cancer
researchProduct

Increased efficacy of stereotactic ablative radiation therapy after bevacizumab in lung oligometastases from colon cancer.

2018

Aim: Metastases from colorectal cancer are poorly responsive to stereotactic ablative radiation therapy (SABR) due to intratumoral hypoxia. Intratumoral oxygenation is improved by administration of angiogenesis inhibitors. Thus, there could be a clinical synergistic effect of SABR with bevacizumab on metastases from colorectal cancer. The aim of this study was to evaluate the feasibility and efficacy of SABR after bevacizumab in lung oligometastases from colon cancer. Methods: The data of patients with lung metastases from colon cancer who underwent SABR were retrospectively evaluated according to the following inclusion criteria: number of metastases ≤3; lung oligometastases from colon can…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyLung NeoplasmsBevacizumabColorectal cancermedicine.medical_treatmentSABR volatility modelRadiosurgery03 medical and health sciences0302 clinical medicineInternal medicineAblative casemedicineHumansAgedRetrospective StudiesLungbusiness.industryGeneral MedicineOxygenationMiddle Agedmedicine.diseaseCombined Modality TherapyRadiation therapyBevacizumab030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisColonic Neoplasmsbusinessmedicine.drugTumori
researchProduct